TABLE 1.
Susceptibility rates and MIC distributions of common antibacterial agents against INS-PA and IS-PA isolates by infection site
| Group of isolates, druga | Value forb: |
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All indicated isolates |
Indicated isolates from: |
||||||||||||||
| BSI |
IAI |
RTI |
UTI |
||||||||||||
| S (%) | MIC50 | MIC90 | S (%) | MIC50 | MIC90 | S (%) | MIC50 | MIC90 | S (%) | MIC50 | MIC90 | S (%) | MIC50 | MIC90 | |
| INS-PA | n = 182 | n = 14 | n = 18 | n = 142 | n = 8 | ||||||||||
| Ceftazidime | 46.7 | 16 | >32 | 50 | 8 | >32 | 56.3 | 8 | >32 | 44.4 | 16 | >32 | 50 | 8 | >32 |
| Cefepime | 51.6 | 8 | >32 | 57.1 | 8 | >32 | 56.3 | 8 | >32 | 50 | 8 | >32 | 50 | 8 | >32 |
| Piperacillin-Tazobactam | 24.7 | >64 | >64 | 21.4 | >64 | >64 | 18.8 | >64 | >64 | 23.9 | >64 | >64 | 37.5 | >64 | >64 |
| Ceftolozane-Tazobactam | 75.3 | 1 | >32 | 78.6 | 1 | >32 | 87.5 | 1 | >32 | 74.6 | 1 | >32 | 50 | 1 | >32 |
| Meropenem | 20.3 | 8 | >32 | 28.57 | 8 | >32 | 25 | 8 | 16 | 18.31 | 8 | >32 | 12.5 | 4 | >32 |
| Aztreonam | 30.2 | >16 | >16 | 21.4 | >16 | >16 | 31.3 | 16 | >16 | 31 | >16 | >16 | 12.5 | >16 | >16 |
| Levofloxacin | 31.3 | 2 | >4 | 21.4 | 2 | >4 | 43.8 | 2 | >4 | 31 | 4 | >4 | 12.5 | >4 | >4 |
| Amikacin | 86.3 | <4 | >32 | 100 | <4 | 8 | 93.8 | <4 | 16 | 85.2 | <4 | >32 | 62.5 | 8 | >32 |
| Tobramycin | 84.1 | <0.5 | >8 | 100 | <0.5 | 1 | 87.5 | <0.5 | >8 | 83.1 | 1 | >8 | 62.5 | 1 | >8 |
| Colistin | 81.3 | 2 | 4 | 64.3 | 2 | 4 | 93.8 | 2 | 2 | 81.7 | 2 | 4 | 87.5 | 2 | 4 |
| IS-PA | n = 340 | n = 32 | n = 39 | n = 232 | n = 37 | ||||||||||
| Ceftazidime | 75.6 | 4 | >32 | 90.6 | 4 | 8 | 76.9 | 4 | 32 | 72.4 | 4 | >32 | 81.1 | 4 | 32 |
| Cefepime | 84.1 | 4 | 16 | 96.9 | 2 | 8 | 87.2 | 4 | 16 | 80.6 | 4 | 16 | 91.9 | 4 | 8 |
| Piperacillin-Tazobactam | 58.8 | 8 | >64 | 81.3 | 8 | >64 | 64.1 | 8 | >64 | 53.4 | 8 | >64 | 67.6 | 8 | >64 |
| Ceftolozane-Tazobactam | 94.7 | 1 | 4 | 100 | 0.5 | 1 | 94.9 | 1 | 2 | 93.5 | 1 | 4 | 97.3 | 1 | 1 |
| Meropenem | 93.8 | 0.5 | 2 | 0.5 | 1 | <0.25 | 0.5 | 4 | <0.25 | 0.5 | 2 | <0.25 | 0.5 | 2 | <0.25 |
| Aztreonam | 69.1 | 8 | >16 | 90.6 | 8 | 8 | 69.2 | 8 | >16 | 63.8 | 8 | >16 | 83.8 | 8 | 16 |
| Levofloxacin | 77.9 | <0.5 | 4 | 90.6 | <0.5 | 1 | 89.7 | <0.5 | 2 | 73.7 | <0.5 | 4 | 81.1 | <0.5 | >4 |
| Amikacin | 99.4 | <4 | 8 | 100 | <4 | <4 | 100 | <4 | <4 | 99.1 | <4 | 8 | 100 | <4 | 8 |
| Tobramycin | 98.2 | <0.5 | 1 | 100 | <0.5 | 1 | 100 | <0.5 | 1 | 97.8 | <0.5 | 1 | 97.3 | <0.5 | 1 |
| Colistin | 82.4 | 2 | 4 | 81.3 | 2 | 4 | 89.7 | 2 | 4 | 81.5 | 2 | 4 | 81.1 | 2 | 4 |
a
INS-PA, imipenem-nonsusceptible Pseudomonas aeruginosa; IS-PA, imipenem-susceptible Pseudomonas aeruginosa.
b
S, susceptible; BSI, bloodstream infection; IAI, intraabdominal tract infection; RTI, respiratory tract infection; UTI, urinary tract infection.